[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SG11202011227VA - Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof - Google Patents

Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof

Info

Publication number
SG11202011227VA
SG11202011227VA SG11202011227VA SG11202011227VA SG11202011227VA SG 11202011227V A SG11202011227V A SG 11202011227VA SG 11202011227V A SG11202011227V A SG 11202011227VA SG 11202011227V A SG11202011227V A SG 11202011227VA SG 11202011227V A SG11202011227V A SG 11202011227VA
Authority
SG
Singapore
Prior art keywords
bisfluoroalkyl
compositions
methods
benzodiazepinone compounds
benzodiazepinone
Prior art date
Application number
SG11202011227VA
Inventor
Bruce S Fischer
Gaurav Bajaj
David Sidransky
Original Assignee
Bristol Myers Squibb Co
Ayala Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co, Ayala Pharmaceuticals Inc filed Critical Bristol Myers Squibb Co
Publication of SG11202011227VA publication Critical patent/SG11202011227VA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/141,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/161,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/181,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202011227VA 2018-05-15 2019-05-15 Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof SG11202011227VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862671748P 2018-05-15 2018-05-15
PCT/US2019/032326 WO2019222298A1 (en) 2018-05-15 2019-05-15 Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof

Publications (1)

Publication Number Publication Date
SG11202011227VA true SG11202011227VA (en) 2020-12-30

Family

ID=68540867

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202011227VA SG11202011227VA (en) 2018-05-15 2019-05-15 Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof

Country Status (11)

Country Link
US (1) US20210220372A1 (en)
EP (1) EP3793563A4 (en)
JP (1) JP2021523189A (en)
KR (1) KR20210008527A (en)
CN (1) CN112236147A (en)
AU (1) AU2019271151A1 (en)
BR (1) BR112020023204A2 (en)
CA (1) CA3100202A1 (en)
MX (2) MX2020012281A (en)
SG (1) SG11202011227VA (en)
WO (1) WO2019222298A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019215585A1 (en) * 2018-05-06 2019-11-14 Ayala Pharmaceuticals Inc. Compositions comprising cd20 inhibitors and bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof
JP2021526517A (en) * 2018-05-24 2021-10-07 アヤラ ファーマシューティカルズ インコーポレイテッド Compositions containing bisfluoroalkyl-1,4-benzodiazepinone compounds and immunotherapeutic agents and methods of their use
SG11202112061RA (en) * 2019-05-15 2021-11-29 Ayala Pharmaceuticals Inc Bisfluoroalkyl-1,4-benzodiazepin one compounds for treating notch-activated breast cancer
US20230047191A1 (en) * 2021-08-05 2023-02-16 Celanese Eva Performance Polymers Llc Implantable Medical Device for the Delivery of Bisphosphonate

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0025173D0 (en) * 2000-10-13 2000-11-29 Merck Sharp & Dohme Therapeutic agents
PT1673347E (en) * 2003-10-06 2015-11-02 Hoffmann La Roche Substituted dibenzo-azepine and benzo-diazepine derivatives useful as gamma-secretase inhibitors
CA2644136A1 (en) * 2006-02-27 2007-09-07 The Johns Hopkins University Cancer treatment with gamma-secretase inhibitors
TWI530489B (en) * 2011-03-22 2016-04-21 必治妥美雅史谷比公司 Bis(fluoroalkyl)-1,4-benzodiazepinone compounds
TWI614238B (en) * 2012-09-21 2018-02-11 必治妥美雅史谷比公司 Bis(fluoroalkyl)-1,4-benzodiazepinone compounds and prodrugs thereof
US9492469B2 (en) * 2013-04-04 2016-11-15 Bristol-Myers Squibb Company Combination therapy for the treatment of proliferative diseases
CN115554406A (en) * 2016-01-07 2023-01-03 博笛生物科技有限公司 anti-CD 20 combinations for the treatment of tumors

Also Published As

Publication number Publication date
KR20210008527A (en) 2021-01-22
WO2019222298A1 (en) 2019-11-21
US20210220372A1 (en) 2021-07-22
JP2021523189A (en) 2021-09-02
MX2020012281A (en) 2021-01-29
AU2019271151A2 (en) 2021-01-14
CA3100202A1 (en) 2019-11-21
AU2019271151A1 (en) 2021-01-07
EP3793563A4 (en) 2022-02-23
CN112236147A (en) 2021-01-15
MX2024007360A (en) 2024-06-28
EP3793563A1 (en) 2021-03-24
BR112020023204A2 (en) 2021-02-23

Similar Documents

Publication Publication Date Title
ZA202007838B (en) Polymerases, compositions, and methods of use
ZA202007839B (en) Polymerases, compositions, and methods of use
IL277079A (en) Cartyrin compositions and methods for use
IL274276A (en) Casz compositions and methods of use
IL280963A (en) Anti-gdf15 antibodies, compositions and methods of use
IL278829A (en) Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and immunotherapeutics and methods of use thereof
GB2582100B (en) CAS12C Compositions and methods of use
IL288278A (en) Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith
PL3557998T3 (en) Compouns, compositions and methods of use
EP3576782A4 (en) Construct-peptide compositions and methods of use thereof
HK1259372A1 (en) Therapeutic compounds, compositions and methods of use thereof
ZA201906169B (en) Synthekine compositions and methods of use
IL283968A (en) Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
IL276135A (en) Compositions and methods of use
IL282939A (en) Mixtures and compositions comprising 5-fluoro-4-imino-3- methyl-1-tosyl-3,4- dihydropyrimidin-2-one, and methods of use thereof
EP3697791A4 (en) Heterocyclic compounds, compositions comprising heterocyclic compound, and methods of use thereof
IL283387A (en) Diarylhydantoin compounds and methods of use thereof
ZA202100780B (en) Bismuth-thiol compositions and methods of use
IL277786A (en) Aav compositions, methods of making and methods of use
SG11202011227VA (en) Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof
SG11202011041YA (en) Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof
HK1258765A1 (en) Therapeutic compounds, compositions and methods of use thereof
EP3426238A4 (en) Curcumin-based compositions&methods of use thereof
EP3735246A4 (en) Mito-lonidamine, compositions and methods of use
GB201808668D0 (en) Compounds and compositions and uses thereof